Cerebrolysin in Alzheimer's disease

Drugs of Today

Volumn 47, Issue 7, 2011, Pages 487-513

  Álvarez, X Antón ^a   Fuentes, Patricio ^b,c  

^a Centro de Investigacion Biomedica EuroEspes   (Spain)

^b HOSPITAL DEL SALVADOR   (Chile)

^c HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE A1 RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CALCIUM; CALPAIN; CEREBROLYSIN; CYCLIN DEPENDENT KINASE 5; DONEPEZIL; GAMMA SECRETASE; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 1BETA; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; RIVASTIGMINE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SUPEROXIDE DISMUTASE; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VINPOCETINE;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BEHAVIOR; BLOOD BRAIN BARRIER; BRAIN METABOLISM; BRAIN MITOCHONDRION; CLINICAL TRIAL (TOPIC); COGNITION; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DAILY LIFE ACTIVITY; DELUSION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPEPSIA; DYSTHYMIA; EXCITOTOXICITY; GASTROINTESTINAL SYMPTOM; GENETIC RISK; HEART ARRHYTHMIA; HEART DISEASE; HEART PALPITATION; HUMAN; HYPOKINESIA; IMMUNOPATHOLOGY; INFLAMMATION; INJECTION SITE BURNING; INJECTION SITE ERYTHEMA; INSOMNIA; INTRACELLULAR SIGNALING; LEARNING; LIPID PEROXIDATION; MACROPHAGE ACTIVATION; MEMORY; METABOLIC DISORDER; MICROGLIA; MILD COGNITIVE IMPAIRMENT; MITOCHONDRIAL TOXICITY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MUSCLE SPASM; NAUSEA; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; NUTRITIONAL DISORDER; OXIDATIVE STRESS; PLEIOTROPY; PROTEIN BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ALZHEIMER DISEASE; AMINO ACIDS; COGNITION; HUMANS; NEURONAL PLASTICITY; NOOTROPIC AGENTS; OXIDATIVE STRESS; SYNAPTIC TRANSMISSION;

EID: 80052776262     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.7.1656496     Document Type: Review

References (168)

1. Lobo, A., Launer, L.J., Fratiglioni, L. et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54(11, Suppl. 5): S4-9.
2. Prince, M., Jackson, J., Alzheimer's Disease International. World Alzheimer Report 2009.
3. Alzheimer's Association. 2010 Alzheimer's disease facts and figures. Alzheimers Dement 2010, 6(2): 158-94.
4. Jellinger, K.A. Clinicopathological analysis of dementia disorders in the elderly - an update. J Alzheimers Dis 2006, 9(3, Suppl.): 61-70.
5. Bertram, L. Alzheimer's disease genetics current status and future perspectives. Int Rev Neurobiol 2009, 84: 167-84.
6. Bertram, L., Tanzi, R.E. Alzheimer disease: New light on an old CLU. Nat Rev Neurol 2010, 6(1): 11-3.
7. Hollingworth, P., Harold, D., Sims, R. et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011, 43(5): 429-35.
8. Naj, A.C., Jun, G., Beecham, G.W. et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2010, 43(5): 436-41.
9. Vargas, T., Martinez-Garcia, A., Antequera, D. et al. IGF-I gene variability is associated with an increased risk for AD. Neurobiol Aging 2011, 32(3): 556 e3-11.
10. Hardy, J., Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580): 353-6.
11. Crews, L., Masliah, E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 2010, 19(R1): R12-20.
12. Palop, J.J., Mucke, L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 2010, 13(7): 812-8.
13. Ittner, L.M., Gotz, J. Amyloid-beta and tau - a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011, 12(2): 65-72.
14. Nelson, P.T., Braak, H., Markesbery, W.R. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 2009, 68(1): 1-14.
15. Iqbal, K., Liu, F., Gong, C.X., Alonso Adel, C., Grundke- Iqbal, I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009, 118(1): 53-69.
16. McGeer, E.G., McGeer, P.L. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis 2010, 19(1): 355-61.
17. Wyss-Coray, T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006, 12(9): 1005-15.
18. Alvarez, A., Cacabelos, R., Sanpedro, C., Garcia-Fantini, M., Aleixandre, M. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging 2007, 28(4): 533-6.
19. Swardfager, W., Lanctot, K., Rothenburg, L., Wong, A., Cappell, J., Herrmann, N. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 2010, 68(10): 930-41.
20. Steen, E., Terry, B.M., Rivera, E.J. et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 2005, 7(1): 63-80.
21. Rivera, E.J., Goldin, A., Fulmer, N., Tavares, R., Wands, J.R., de la Monte, S.M. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005, 8(3): 247-68.
22. Mufson, E.J., Counts, S.E., Fahnestock, M., Ginsberg, S.D. Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr Alzheimer Res 2007, 4(4): 340-50.
23. Mufson, E.J., Counts, S.E., Perez, S.E., Ginsberg, S.D. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother 2008, 8(11): 1703-18.
24. Schindowski, K., Belarbi, K., Buee, L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav 2008, 7(Suppl. 1): 43-56.
25. Zuccato, C., Cattaneo, E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 2009, 5(6): 311-22.
26. Smith, M.A., Zhu, X., Tabaton, M. et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 2010, 19(1): 363-72.
27. Bezprozvanny, I., Mattson, M.P. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 2008, 31(9): 454-63.
28. Kapogiannis, D., Mattson, M.P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol 2011, 10(2): 187-98.
29. Mosconi, L., Pupi, A., De Leon, M.J. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 2008, 1147: 180-95.
30. Mosconi, L., Berti, V., Glodzik, L., Pupi, A., De Santi, S., de Leon, M.J. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis 2010, 20(3): 843-54.
31. Cummings, J.L. Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies. Rev Neurol Dis 2007, 4(2): 57-62.
32. Seow, D., Gauthier, S. Pharmacotherapy of Alzheimer disease. Can J Psychiatry 2007, 52(10): 620-9.
33. Raina, P., Santaguida, P., Ismaila, A. et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008, 148(5): 379-97.
34. Tuszynski, M.H. Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2007, 21(2): 179-89.
35. Cattaneo, A., Capsoni, S., Paoletti, F. Towards non invasive nerve growth factor therapies for Alzheimer's disease. J Alzheimers Dis 2008, 15(2): 255-83.
36. Salloway, S., Mintzer, J., Weiner, M.F., Cummings, J.L. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement 2008, 4(2): 65-79.
37. Wisniewski, T., Konietzko, U. Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol 2008, 7(9): 805-11.
38. Plosker, G.L., Gauthier, S. Cerebrolysin: a review of its use in dementia. Drugs Aging 2009, 26(11): 893-915.
39. Plosker, G.L., Gauthier, S. Spotlight on cerebrolysin in dementia. CNS Drugs 2010, 24(3): 263-6.
40. Chen, H., Tung, Y.C., Li, B., Iqbal, K., Grundke-Iqbal, I. Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol Aging 2007, 28(8): 1148-62.
41. Frey II, W.H., Hanson, L.R., Liu, X-F., et al. Quantitative and qualitative distribution of 125I-labeled Cerebrolysin peptides in the CNS following IN delivery. Unterach, Austria: Ebewe Neuro Pharma GmbH, 2005: Data on file.
42. Gschanes, A., Valouskova, V., Windisch, M. Ameliorative influence of a nootropic drug on motor activity of rats after bilateral carotid artery occlusion. J Neural Transm 1997, 104(11-12): 1319-27.
43. Akai, F., Hiruma, S., Sato, T., Iwamoto, N., Fujimoto, M., Ioku, M., Hashimoto, S. Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain. Histol Histopathol 1992, 7(2): 213-21.
44. Francis-Turner, L., Valouskova, V. Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbriafornix transection: short-term study. Neurosci Lett 1996, 202(3): 193-6.
45. Rockenstein, E., Mallory, M., Mante, M., Alford, M., Windisch, M., Moessler, H., Masliah, E. Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease. J Neural Transm Suppl 2002(62): 327-36.
46. Rockenstein, E., Adame, A., Mante, M., Moessler, H., Windisch, M., Masliah, E. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J Neural Transm 2003, 110(11): 1313-27.
47. Rockenstein, E., Adame, A., Mante, M. et al. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. J Neural Transm 2005, 112(2): 269-82.
48. Rockenstein, E., Torrance, M., Mante, M. et al. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J Neurosci Res 2006, 83(7): 1252-61.
49. Ubhi, K., Rockenstein, E., Doppler, E. et al. Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin. Acta Neuropathol 2009, 117(6): 699-712.
50. Rockenstein, E., Ubhi, K., Pham, E. et al. Long-term therapeutical efficacy following Cerebrolysin treatment interruption in a transgenic mouse model of Alzheimer's disease. J Neurosci Res 2011: Submitted.
51. Rockenstein, E., Mante, M., Adame, A., Crews, L., Moessler, H., Masliah, E. Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease. Acta Neuropathol 2007, 113(3): 265-75.
52. Álvarez, X.A., Fernández-Novoa, L., Sampedro, C., Lombardi, V., Windisch, M., Cacabelos, R. Neuroimmunotrophic effects of Cerebrolysin in an animal model of hippocampal degeneration induced by beta-amyloid. In:Vol. Vascular Dementia. A.D. Korczyn (Ed.). Monduzzi Editore: Bologna 1999, 233-37.
53. Álvarez, X.A., de Olano, M., Sampedro, C., Lombardi, V., Moessler, H., Windisch, M., Cacabelos, R. Cerebrolysin protects against neurodegeneration induced by beta-amyloid in rats. Int J Neuropsychopharmacol [XXII CINP Congr (July 9-13, Brussels) 2000] 2000, 3(Suppl. 1): S359.
54. Alvarez, X.A., Lombardi, V.R., Fernandez-Novoa, L. et al. Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. J Neural Transm Suppl 2000, 59: 281-92.
55. Lombardi, V.R., Windisch, M., Garcia, M., Cacabelos, R. Effects of Cerebrolysin on in vitro primary microglial and astrocyte rat cell cultures. Methods Find Exp Clin Pharmacol 1999, 21(5): 331-8.
56. Alvarez, X.A., Cacabelos, R., Laredo, M. et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 2006, 13(1): 43-54.
57. Anton Alvarez, X., Sampedro, C., Cacabelos, R., Linares, C., Aleixandre, M., Garcia-Fantini, M., Moessler, H. Reduced TNF-alpha and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent Cerebrolysin. Int J Neuropsychopharmacol 2009, 12(7): 867-72.
58. Anton Alvarez, X., Cacabelos, R., Sampedro, C. et al. Combination treatment in Alzheimer's disease: Results of a randomized, controlled trial with Cerebrolysin and donepezil. Curr Alzheimer Res 2011: Advance publication.
59. Alvarez, X.A., Sampedro, C., Cacabelos, R., Aleixandre, M., Doppler, E., Novak, P., Moessler, H. Neurotrophic and combined treatment in Alzheimer's disease: Modulatory effects on free IGF-I and TNF-alpha. Neurodegener Dis [10th Int Conf AD/PD (March 9-13, Barcelona) 2011] 2011, 8(S1): P438.
60. Satou, T., Itoh, T., Fujimoto, M., Hashimoto, S. [Neurotrophic-like effects of FPF-1070 on cultured neurons from chick embryonic dorsal root ganglia]. Jpn Pharmacol Ther 1994, 22(4): 205-12.
61. Satou, T., Itoh, T., Tamai, Y., Ohde, H., Anderson, A.J., Hashimoto, S. Neurotrophic effects of FPF-1070 (Cerebrolysin) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks. J Neural Transm 2000, 107(11): 1253-62.
62. Valouskova, V., Francis-Turner, L. Can Cerebrolysin influence chronic deterioration of spatial learning and memory? J Neural Transm Suppl 1998, 53: 343-9.
63. Haninec, P., Houst'ava, L., Stejskal, L., Dubovy, P. Rescue of rat spinal motoneurons from avulsion-induced cell death by intrathecal administration of IGF-I and Cerebrolysin. Ann Anat 2003, 185(3): 233-8.
64. Haninec, P., Dubovy, P., Samal, F., Houstava, L., Stejskal, L. Reinnervation of the rat musculocutaneous nerve stump after its direct reconnection with the C5 spinal cord segment by the nerve graft following avulsion of the ventral spinal roots: a comparison of intrathecal administration of brainderived neurotrophic factor and Cerebrolysin. Exp Brain Res 2004, 159(4): 425-32.
65. Hartbauer, M., Hutter-Paier, B., Skofitsch, G., Windisch, M. Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm 2001, 108(4): 459-73.
66. Mallory, M., Honer, W., Hsu, L., Johnson, R., Rockenstein, E., Masliah, E. In vitro synaptotrophic effects of Cerebrolysin in NT2N cells. Acta Neuropathol 1999, 97(5): 437-46.
67. Reinprecht, I., Gschanes, A., Windisch, M., Fachbach, G. Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old rats. Histochem J 1999, 31(6): 395-401.
68. Windholz, E., Gschanes, A., Windisch, M., Fachbach, G. Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 6-week-old rats. Histochem J 2000, 32(2): 79-84.
69. Masliah, E., Armasolo, F., Veinbergs, I., Mallory, M., Samuel, W. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Behav 1999, 62(2): 239-45.
70. Alvarez, X.A. Study of the effects of Cerebrolysin on serum BDNF levels in patients with probable Alzheimer's disease. Cere-BDNF Integrated Report. Unterach, Austria: Ever Neuro Pharma GmbH, May 2011: Data on file.
71. Patockova, J., Krsiak, M., Marhol, P., Tumova, E. Cerebrolysin inhibits lipid peroxidation induced by insulin hypoglycemia in the brain and heart of mice. Physiol Res 2003, 52(4): 455-60.
72. Guzman, D.C., Brizuela, N.O., Alvarez, R.G., Garcia, E.H., Mejia, G.B., Olguin, H.J. Cerebrolysin and morphine decrease glutathione and 5-hydroxyindole acetic acid levels in fasted rat brain. Biomed Pharmacother 2009, 63(7): 517-21.
73. Gonzalez, M.E., Francis, L., Castellano, O. Antioxidant systemic effect of short-term Cerebrolysin administration. J Neural Transm Suppl 1998, 53: 333-41.
74. Hutter-Paier, B., Grygar, E., Fruhwirth, M., Temmel, I., Windisch, M. Further evidence that Cerebrolysin protects cortical neurons from neurodegeneration in vitro. J Neural Transm Suppl 1998, 53: 363-72.
75. Hutter-Paier, B., Steiner, E., Windisch, M. Cerebrolysin protects isolated cortical neurons from neurodegeneration after brief histotoxic hypoxia. J Neural Transm Suppl 1998, 53: 351-61.
76. Buresh, Y., Koroleva, V.I., Korolev, O.S., Maresh, V. Changes in the constant potential in brain structures in rats during focal ischemia and systemic hypoxia. Neurosci Behav Physiol 1999, 29(5): 569-79.
77. Koroleva, V.I., Korolev, O.S., Mares, V., Pastalkova, E., Bures, J. Hippocampal damage induced by carbon monoxide poisoning and spreading depression is alleviated by chronic treatment with brain derived polypeptides. Brain Res 1999, 816(2): 618-27.
78. Schwab, M., Antonow-Schlorke, I., Zwiener, U., Bauer, R. Brain-derived peptides reduce the size of cerebral infarction and loss of MAP2 immunoreactivity after focal ischemia in rats. J Neural Transm Suppl 1998, 53: 299-311.
79. Hartbauer, M., Hutter-Paie, B., Windisch, M. Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons. J Neural Transm 2001, 108(5): 581-92.
80. Gutmann, B., Hutter-Paier, B., Skofitsch, G., Windisch, M., Gmeinbauer, R. In vitro models of brain ischemia: the peptidergic drug cerebrolysin protects cultured chick cortical neurons from cell death. Neurotox Res 2002, 4(1): 59-65.
81. Schauer, E., Wronski, R., Patockova, J., Moessler, H., Doppler, E., Hutter-Paier, B., Windisch, M. Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window. J Neural Transm 2006, 113(7): 855-68.
82. Sharma, H.S., Muresanu, D., Sharma, A., Zimmermann- Meinzingen, S. Cerebrolysin treatment attenuates heat shock protein overexpression in the brain following heat stress: an experimental study using immunohistochemistry at light and electron microscopy in the rat. Ann N Y Acad Sci 2010, 1199: 138-48.
83. Hutter-Paier, B., Grygar, E., Windisch, M. Death of cultured telencephalon neurons induced by glutamate is reduced by the peptide derivative Cerebrolysin. J Neural Transm Suppl 1996, 47: 267-73.
84. Riley, C., Hutter-Paier, B., Windisch, M., Doppler, E., Moessler, H., Wronski, R. A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxication. J Neural Transm 2006, 113(1): 103-10.
85. Veinbergs, I., Mante, M., Mallory, M., Masliah, E. Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity. J Neural Transm Suppl 2000, 59: 273-80.
86. Wronski, R., Tompa, P., Hutter-Paier, B., Crailsheim, K., Friedrich, P., Windisch, M. Inhibitory effect of a brain derived peptide preparation on the Ca++-dependent protease, calpain. J Neural Transm 2000, 107(2): 145-57.
87. Vosler, P.S., Brennan, C.S., Chen, J. Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol Neurobiol 2008, 38(1): 78-100.
88. Baskys, A., Wojtowicz, J.M. Effects of brain tissue hydrolysate on synaptic transmission in the hippocampus. Pharmacol Biochem Behav 1994, 49(4): 1105-7.
89. Xiong, H., Wojtowicz, J.M., Baskys, A. Brain tissue hydrolysate acts on presynaptic adenosine receptors in the rat hippocampus. Can J Physiol Pharmacol 1995, 73(8): 1194-7.
90. Xiong, H., Baskys, A., Wojtowicz, J.M. Brain-derived peptides inhibit synaptic transmission via presynaptic GABAB receptors in CA1 area of rat hippocampal slices. Brain Res 1996, 737(1-2): 188-94.
91. Zemkova, H., Kruek, J., Vyskocil, F. Potentiation of GABAA receptor in cultured mouse hippocampal cells by brainderived peptide mixture cerebrolysin. Physiol Res 1995, 44(3): 151-5.
92. Froestl, W. Novel GABA(B) receptor positive modulators: a patent survey. Expert Opin Ther Pat 2010, 20(8): 1007-17.
93. Fiorentino, H., Kuczewski, N., Diabira, D., Ferrand, N., Pangalos, M.N., Porcher, C., Gaiarsa, J.L. GABA(B) receptor activation triggers BDNF release and promotes the maturation of GABAergic synapses. J Neurosci 2009, 29(37): 11650-61.
94. Hasko, G., Linden, J., Cronstein, B., Pacher, P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008, 7(9): 759-70.
95. Sebastiao, A.M., Ribeiro, J.A. Adenosine receptors and the central nervous system. Handb Exp Pharmacol 2009(193): 471-534.
96. Romagnoli, R., Baraldi, P.G., Tabrizi, M.A., Gessi, S., Borea, P.A., Merighi, S. Allosteric enhancers of A1 adenosine receptors: state of the art and new horizons for drug development. Curr Med Chem 2010, 17(30): 3488-502.
97. Eder, P., Reinprecht, I., Schreiner, E., Skofitsch, G., Windisch, M. Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: an immunohistochemical study on aged rats. Histochem J 2001, 33(11-12): 605-12.
98. Sanderson, D.J., Good, M.A., Seeburg, P.H., Sprengel, R., Rawlins, J.N., Bannerman, D.M. The role of the GluR-A (GluR1) AMPA receptor subunit in learning and memory. Prog Brain Res 2008, 169: 159-78.
99. Baran, H., Kepplinger, B. Cerebrolysin lowers kynurenic acid formation - an in vitro study. Eur Neuropsychopharmacol 2009, 19(3): 161-8.
100. Boado, R.J. Brain-derived peptides increase blood-brain barrier GLUT1 glucose transporter gene expression via mRNA stabilization. Neurosci Lett 1998, 255(3): 147-50.
101. Boado, R.J., Wu, D., Windisch, M. In vivo upregulation of the blood-brain barrier GLUT1 glucose transporter by brainderived peptides. Neurosci Res 1999, 34(4): 217-24.
102. Gschanes, A., Boado, R., Sametz, W., Windisch, M. The drug cerebrolysin and its peptide fraction E021 increase the abundance of the blood-brain barrier GLUT1 glucose transporter in brains of young and old rats. Histochem J 2000, 32(2): 71-7.
103. Boado, R.J. Amplification of blood-brain barrier GLUT1 glucose transporter gene expression by brain-derived peptides. Neurosci Res 2001, 40(4): 337-42.
104. Dierks, T., Jelic, V., Pascual-Marqui, R.D. et al. Spatial pattern of cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-generators in Alzheimer's disease. Clin Neurophysiol 2000, 111(10): 1817-24.
105. Alvarez, X.A., Lombardi, V.R., Corzo, L. et al. Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects. J Neural Transm Suppl 2000, 59: 315-28.
106. Gorbachevskaya, N., Bashina, V., Gratchev, V., Iznak, A. Cerebrolysin therapy in Rett syndrome: clinical and EEG mapping study. Brain Dev 2001, 23(Suppl. 1): S90-3.
107. Alvarez, X.A., Sampedro, C., Perez, P. et al. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study. Int Clin Psychopharmacol 2003, 18(5): 271-8.
108. Alvarez, X.A., Sampedro, C., Figueroa, J. et al. Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury. J Neural Transm 2008, 115(5): 683-92.
109. Muresanu, D.F., Alvarez, X.A., Moessler, H. et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. J Neurol Sci 2008, 267(1-2): 112-9.
110. Muresanu, D.F., Alvarez, X.A., Moessler, H. et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study. J Neurol Sci 2010, 299(1-2): 179-83.
111. Álvarez, X.A., Sampedro, C., Pérez, P. et al. Cerebrolysin improves brain bioelectrical activity pattern and cognitive functioning in traumatic brain injury and in senile dementia. Int J Neuropsychopharmacol [XXII CINP Cong (June 23-27, Montreal) 2002] 2002, 5(Suppl. 1): S92.
112. Funke, M., Fiehler, J., Mewes, I., Eiselt, M., Rother, I., Windisch, M. Dose-dependent effects of Cerebrolysin on EEG and short-term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia. J Neural Transm Suppl 1998, 53: 385-98.
113. Safarova, E.R., Shram, S.I., Grivennikov, I.A., Myasoedov, N.F. Trophic effects of nootropic peptide preparations cerebrolysin and semax on cultured rat pheochromocytoma. Bull Exp Biol Med 2002, 133(4): 401-3.
114. Juarez, I., Gonzalez, D.J., Mena, R., Flores, G. The chronic administration of cerebrolysin induces plastic changes in the prefrontal cortex and dentate gyrus in aged mice. Synapse 2011: Advance publication.
115. Tatebayashi, Y., Lee, M.H., Li, L., Iqbal, K., Grundke-Iqbal, I. The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease. Acta Neuropathol 2003, 105(3): 225-32.
116. Wronski, R., Kronawetter, S., Hutter-Paier, B., Crailsheim, K., Windisch, M. A brain derived peptide preparation reduces the translation dependent loss of a cytoskeletal protein in primary cultured chicken neurons. J Neural Transm Suppl 2000, 59: 263-72.
117. Doppler, E., Rockenstein, E., Ubhi, K. et al. Neurotrophic effects of Cerebrolysin in the Mecp2(308/Y) transgenic model of Rett syndrome. Acta Neuropathol 2008, 116(4): 425-37.
118. Rohn, T.T., Head, E. Caspase activation in Alzheimer's disease: early to rise and late to bed. Rev Neurosci 2008, 19(6): 383-93.
119. Zhang, C., Chopp, M., Cui, Y. et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res 2010, 88(15): 3275-81.
120. Gschanes, A., Windisch, M. The influence of Cerebrolysin and E021 on spatial navigation of 24-month-old rats. J Neural Transm Suppl 1998, 53: 313-21.
121. Gschanes, A., Windisch, M. Early postnatal treatment with peptide preparations influences spatial navigation of young and adult rats. Behav Brain Res 1999, 100(1-2): 161-6.
122. Valouskova, V., Gschanes, A. Effects of NGF, b-FGF, and cerebrolysin on water maze performance and on motor activity of rats: short- and long-term study. Neurobiol Learn Mem 1999, 71(2): 132-49.
123. Hutter-Paier, B., Eggenreich, U., Windisch, M. Effects of two protein-free peptide derivatives on passive avoidance behaviour of 24-month-old rats. Arzneimittelforschung 1996, 46(3): 237-41.
124. Hutter-Paier, B., Eggenreich, U., Windisch, M. Dosedependent behavioural effects of two protein-free peptide derivatives on the passive avoidance reaction of rats. Arzneimittelforschung 1996, 46(3): 242-6.
125. Gualco, E., Wang, J.Y., Del Valle, L. et al. IGF-IR in neuroprotection and brain tumors. Front Biosci 2009, 14: 352-75.
126. Nagahara, A.H., Tuszynski, M.H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 2011, 10(3): 209-19.
127. Wada, A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J Pharmacol Sci 2009, 110(1): 14-28.
128. Frame, S., Cohen, P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001, 359(Pt. 1): 1-16.
129. Hooper, C., Killick, R., Lovestone, S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 2008, 104(6): 1433-9.
130. Nikolaev, A., McLaughlin, T., O'Leary, D.D., Tessier-Lavigne, M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009, 457(7232): 981-9.
131. Nagahara, A.H., Merrill, D.A., Coppola, G. et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009, 15(3): 331-7.
132. Carro, E., Trejo, J.L., Spuch, C., Bohl, D., Heard, J.M., Torres- Aleman, I. Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? Neurobiol Aging 2006, 27(11): 1618-31.
133. Carro, E., Trejo, J.L., Gomez-Isla, T., LeRoith, D., Torres- Aleman, I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 2002, 8(12): 1390-7.
134. Dong, W., Albers, J.J., Vuletic, S. Phospholipid transfer protein reduces phosphorylation of tau in human neuronal cells. J Neurosci Res 2009, 87(14): 3176-85.
135. Kidd, L.B., Schabbauer, G.A., Luyendyk, J.P., Holscher, T.D., Tilley, R.E., Tencati, M., Mackman, N. Insulin activation of the phosphatidylinositol 3-kinase/protein kinase B (Akt) pathway reduces lipopolysaccharide-induced inflammation in mice. J Pharmacol Exp Ther 2008, 326(1): 348-53.
136. Jimenez, S., Torres, M., Vizuete, M. et al. Age-dependent Accumulation of Soluble Amyloid {beta} (A{beta}) Oligomers Reverses the Neuroprotective Effect of Soluble Amyloid Precursor Protein-{alpha} (sAPP{alpha}) by Modulating Phosphatidylinositol 3-Kinase (PI3K)/Akt-GSK-3{beta} Pathway in Alzheimer Mouse Model. J Biol Chem 2011, 286(21): 18414-25.
137. Nguyen, T.L., Kim, C.K., Cho, J.H., Lee, K.H., Ahn, J.Y. Neuroprotection signaling pathway of nerve growth factor and brain-derived neurotrophic factor against staurosporine induced apoptosis in hippocampal H19-7/IGF-IR [corrected]. Exp Mol Med 2010, 42(8): 583-95.
138. Leinninger, G.M., Backus, C., Uhler, M.D., Lentz, S.I., Feldman, E.L. Phosphatidylinositol 3-kinase and Akt effectors mediate insulin-like growth factor-I neuroprotection in dorsal root ganglia neurons. FASEB J 2004, 18(13): 1544-6.
139. Nagahara, A.H., Bernot, T., Moseanko, R. et al. Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Exp Neurol 2009, 215(1): 153-9.
140. Burkhalter, J., Fiumelli, H., Allaman, I., Chatton, J.Y., Martin, J.L. Brain-derived neurotrophic factor stimulates energy metabolism in developing cortical neurons. J Neurosci 2003, 23(23): 8212-20.
141. Chan, J.P., Cordeira, J., Calderon, G.A., Iyer, L.K., Rios, M. Depletion of central BDNF in mice impedes terminal differentiation of new granule neurons in the adult hippocampus. Mol Cell Neurosci 2008, 39(3): 372-83.
142. Ortega, F., Perez-Sen, R., Morente, V., Delicado, E.G., Miras-Portugal, M.T. P2X7, NMDA and BDNF receptors converge on GSK3 phosphorylation and cooperate to promote survival in cerebellar granule neurons. Cell Mol Life Sci 2010, 67(10): 1723-33.
143. Eom, T.Y., Roth, K.A., Jope, R.S. Neural precursor cells are protected from apoptosis induced by trophic factor withdrawal or genotoxic stress by inhibitors of glycogen synthase kinase 3. J Biol Chem 2007, 282(31): 22856-64.
144. Bath, K.G., Lee, F.S. Neurotrophic factor control of adult SVZ neurogenesis. Dev Neurobiol 2010, 70(5): 339-49.
145. Sereno, L., Coma, M., Rodriguez, M. et al. A novel GSK- 3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 2009, 35(3): 359-67.
146. Bolos, M., Fernandez, S., Torres-Aleman, I. Oral administration of a GSK3 inhibitor increases brain insulin-like growth factor I levels. J Biol Chem 2010, 285(23): 17693-700.
147. Buller, C.L., Loberg, R.D., Fan, M.H. et al. A GSK- 3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Physiol 2008, 295(3): C836-43.
148. Ruether, E., Husmann, R., Kinzler, E. et al. A 28-week, double- blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. Int Clin Psychopharmacol 2001, 16(5): 253-63.
149. Ruther, E., Ritter, R., Apecechea, M., Freytag, S., Gmeinbauer, R., Windisch, M. Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy. J Neural Transm 2000, 107(7): 815-29.
150. Ren, J., Sietsma, D., Qiu, S., Moessler, H., Finklestein, S.P. Cerebrolysin enhances functional recovery following focal cerebral infarction in rats. Restor Neurol Neurosci 2007, 25(1): 25-31.
151. Alvarez, X.A., Cacabelos, R., Sampedro, C. et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol 2011, 18(1): 59-68.
152. Counts, S.E., Nadeem, M., Lad, S.P., Wuu, J., Mufson, E.J. Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropathol Exp Neurol 2006, 65(6): 592-601.
153. Scheff, S.W., Price, D.A., Schmitt, F.A., Mufson, E.J. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2006, 27(10): 1372-84.
154. Frautschy, S.A., Cole, G.M. Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol 2010, 41(2-3): 392-409.
155. Cortes, F., Portet, F., Touchon, J., Vellas, B. Six and 18- month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials? J Nutr Health Aging 2007, 11(4): 330-7.
156. Mufson, E.J., Wuu, J., Counts, S.E., Nykjaer, A. Preservation of cortical sortilin protein levels in MCI and Alzheimer's disease. Neurosci Lett 2010, 471(3): 129-33.
157. Hebenstreit, G.F. Die Wirkung eines Aminosaure-Peptides- Extractes bei zerebralen Funktionsitorungen in der Gerontopsychiatre. Neuropsychiatre 1986, 1(1): 38-44.
158. Ruther, E., Ritter, R., Apecechea, M., Freytag, S., Windisch, M. Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 1994, 27(1): 32-40.
159. Xiao, S., Yan, H., Yao, P., and the Cerebrolysin Study Group. Efficacy of FPF 1070 (Cerebrolysin) in patients with Alzheimer's disease: A multicentre, randomized, doubleblind, placebo-controlled trial. Clin Drug Investig 2000, 19(1): 43-53.
160. Bae, C.Y., Cho, C.Y., Cho, K. et al. A double-blind, placebocontrolled, multicenter study of Cerebrolysin for Alzheimer's disease. J Am Geriatr Soc 2000, 48(12): 1566-71.
161. Panisset, M., Gauthier, S., Moessler, H., Windisch, M. Cerebrolysin in Alzheimer's disease: a randomized, doubleblind, placebo-controlled trial with a neurotrophic agent. J Neural Transm 2002, 109(7-8): 1089-104.
162. Muresanu, D.F., Rainer, M., Moessler, H. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin. J Neural Transm Suppl 2002(62): 277-85.
163. Gavrilova, S.I., Kolykhalov, I.V., Korovaitseva, G.I., Zharikov, G.A., Kalyn Ia, B., Selezneva, N.D. [ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease]. Zh Nevrol Psikhiatr Im S S Korsakova 2005, 105(4): 27-34.
164. Ruether, E., Alvarez, X.A., Rainer, M., Moessler, H. Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: a double- blind, placebo-controlled study with the neurotrophic agent Cerebrolysin. J Neural Transm Suppl 2002(62): 265-75.
165. Wei, Z.H., He, Q.B., Wang, H., Su, B.H., Chen, H.Z. Metaanalysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. J Neural Transm 2007, 114(5): 629-34.
166. Himmerich, H., Fulda, S., Linseisen, J. et al. Depression, comorbidities and the TNF-alpha system. Eur Psychiatry 2008, 23(6): 421-9.
167. O'Brien, S.M., Scully, P., Fitzgerald, P., Scott, L.V., Dinan, T.G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007, 41(3-4): 326-31.
168. Gavrilova, S.I., Kolykhalov, I.V., Fedorova, Y.B. et al. Potential of preventive treatment of Alzheimer's disease: results of a three-year prospective open comparative trial of the efficacy and safety of courses of treatment with cerebrolysin and cavinton in elderly patients with mild cognitive impairment syndrome. Neurosci Behav Physiol 2011, 41(4): 391-8.